Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T3 Phase IB Trial of the Lysa Group

被引：17

作者：

Le Gouill, Steven ^{[1
,2
]}

Bouabdallah, Krimo ^{[3
]}

Burroni, Barbara ^{[4
]}

Lamy, Thierry ^{[5
]}

Gressin, Remy ^{[6
]}

Cartron, Guillaume ^{[7
]}

Thieblemont, Catherine ^{[8
]}

Sarkozy, Clementine ^{[9
]}

Haioun, Corinne ^{[10
]}

Casasnovas, Olivier ^{[11
]}

Gyan, Emmanuel ^{[12
]}

Hermine, Olivier ^{[13
]}

机构：

[1] Nantes Univ Hosp, Dept Hematol, Nantes, France

[2] INSERM, UMR892, Nantes, France

[3] CHU Bordeaux, Haematol, Bordeaux, France

[4] Cochin Univ Hosp, AP HP, Pathol Dept, Paris, France

[5] CHU Pontchaillou, INSERM, U917, Rennes, France

[6] CHU Grenoble, Hematol, Grenoble, France

[7] CHR Univ Tours, Montpellier, France

[8] Hop St Louis, Paris, France

[9] Hosp Civils Lyon, Hematol, Pierre Benite, France

[10] Grp Hosp Mondor, AP HP, Lymphoid Malignancies Unit, Creteil, France

[11] CHU Dijon, Hop Le Bocage, Hematol Dept, Dijon, France

[12] Ctr Hosp Univ, Serv Hematol & Therapie Cellulaire, Tours, France

[13] Necker Univ Hosp, AP HP, Hematol Dept, Paris, France

来源：

关键词：

D O I：

10.1182/blood.V128.22.2987.2987

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2987

引用

页数：6